

Date of the CVA	06/04/2021
------------------------	------------

Section A. PERSONAL DATA

Name and Surname	Carlos Camps Herrero		
DNI	22517012N	Age	67
Researcher's identification number	Researcher ID	L-3073-2017	
	Scopus Author ID	35407295500	
	ORCID	0000-0002-0648-5403	

* Obligatorio

A.1. Current professional situation

Institution	Consorcio Htal Gral Universitario de Valencia/ Universitat de València		
Dpt. / Centre	Servicio Oncología Médica/ Dep. Medicina / Servicio Oncología Médica/ Dep. Medicina		
Address	Consorcio Hospital General de Valencia, Av.Tres Cruces s/n, 46014, Valencia		
Phone	636 224 107	Email	camps_car@gva.es
Professional category	Jefe de Servicio (2003)/ Catedrático de Universidad (2018)	Start date	2018
Keywords	Clinical medicine and epidemiology; Biomedicine; Molecular, cellular and genetic biology		

A.2. Academic education (Degrees, institutions, dates)

Bachelor/Master/PhD	University	Year
Doctor en Medicina y Cirugía	Facultad de Medicina de la Universidad de Valencia,	1983

A.3. General quality indicators of scientific production

H Index: 38. No. of publications in First Decile: 48. No. of Publications in First Quartile: 81. No. Publications as First Author: 28. No. publications as last or corresponding author: 36. Total number of publications: 227. Cumulative Impact Factor: 1.076. Number of citations: 9733.

Section B. SUMMARY OF THE CURRICULUM

Dr. Carlos Camps is Head of the Medical Oncology Service at the General Hospital of Valencia and Professor of the Department of Medicine at the University of Valencia. He has 5 six-year research and one six-year of knowledge transfer by the CNEAI. He has been Mentor of 14 doctoral theses and 18 End-of-Degree and End-of-Master Projects. He has been President of ASEICA (2017-2018) and the ECO Foundation (Excellence and Quality in Oncology), Vice President of the Spanish Lung Cancer Group (2016 - up to the present), Member of the National Commission of Oncology Speciality (2014 - up to the present), Vice president of the National Commission of Oncology Speciality (2020-). He is also a Member of the Scientific Steering Committee at the General University Hospital Foundation of Valencia, ETOP (European Thoracic Oncology Platform), Scientific Committee of the French Ministry of Health, National Cancer Institute of France (INCa) and the Italian Association of Medical Oncology (AIOM). He is Evaluator for ANECA, ANEP, Cancer Research UK, Regional Government of Galicia and the Andalusian Public Foundation Progress and Health. Member of the Scientific Societies: ASEICA, SEOM, AACR, IASLC, ASCO, EACR and ESMO.

As Principal Investigator, he has an extensive experience recruiting HR for his research group in competitive calls: pre- and post-doctoral contracts of the Regional Government of Valencia (APOSTD / 2019/087; CAGI-05/20-A; ACIF /2017/128), AECC, ISCIII and MINECO (FPU14 / 06911).

Section C. MOST RELEVANT MERITS (ordered by typology)

C.1. Publications

AC: Autor de correspondencia; (nº x / nº y): posición firma solicitante / total autores

- 1 **Scientific paper.** Alejandro Herreros-Pomares; Xuan Zhou; Silvia Calabuig-Fariñas; et al; Carlos Camps (AC); Lijie Grace Zhang. (9/10). 2021. 3D printing novel in vitro cancer cell culture model systems for lung cancer stem cell study *Materials Science & Engineering C-Materials for Biological Applications*. 122-111914.
- 2 **Scientific paper.** Andrea Moreno-Manuel; Eloisa Jantus-Lewintre; Ines Simões; et al; Carlos Camps; Rafael Sirera. (10/12). 2020. CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancer *Translational Lung Cancer Research*. AME. 9-4, pp.1074-1083.
- 3 **Scientific paper.** Susana Torres; Álvaro González; Alberto Jacobo Cunquero Tomas; et al; Carlos Camps. (9/9). 2020. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer. *Expert Review Of Molecular Diagnostics*. pp.1-8. ISSN 1473-7159.
- 4 **Scientific paper.** Camps C; Badia X; García-Campelo R; et al; Guillem V.(1/10). 2020. Development of a Multicriteria Decision Analysis Framework for Evaluating and Positioning Oncologic Treatments in Clinical Practice. *Journal of Clinical Oncology Practice*. American Society of Clinical Oncology. 16-3. ISSN 2688-1527.
- 5 **Scientific paper.** Jon Zugazagoitia; Ana Gómez-Rueda; Eloisa Jantus-Lewintre; et al; Carlos Camps; Pilar Garrido. (5/19). 2019. Clinical Utility of Plasma-Based Digital Next-Generation Sequencing in Oncogene-Driven Non-Small-Cell Lung Cancer Patients With Tyrosine Kinase Inhibitor Resistance *Lung Cancer*. 134, pp.72-78. ISSN 0169-5002.
- 6 **Scientific paper.** Jordi Remon Masip; Gilberto Lopes; Carlos Camps. (3/3). 2019. How sustainable are new treatment strategies for NSCLC? *Lancet Respiratory Medicine*. Elsevier. 19, pp.1-3. ISSN 2213-2600.
- 7 **Scientific paper.** Maria Villalba, Esther Redin; Francisco Exposito; Maria Jose Pajares; et al; Rafael Lopez-Lopez; Alfonso Calvo. (14/20). 2019. Identification of a Novel Synthetic Lethal Vulnerability in Non-Small Cell Lung Cancer by Co-Targeting TMPRSS4 and DDR1 *Scientific Reports*. 9-1, pp.15400. ISSN 2045-2322.
- 8 **Scientific paper.** Mariano Provencio; Enric Carcereny; Delvys Rodríguez-Abreu; et al; Carlos Camps; Elvira Del Barco. (6/17). 2019. Lung Cancer in Spain: Information From the Thoracic Tumors Registry (TTR Study) *Translational Lung Cancer Research*. Pioneer Bioscience Publishing Company. 8-4, pp.461-475. ISSN 2218-6751.
- 9 **Scientific paper.** Herreros-Pomares A; de-Maya-Girones; Calabuig-Fariñas S; et al; Camps C. (AC). (19/19). 2019. Lung Tumors reveal cancer stem cell-like properties and a score with prognostic impact in resected non-small-cell lung cancer. *Cell Death & Disease*. 10-9, pp.660-674. ISSN 2041-4889.
- 10 **Scientific paper.** Dolores Isla; Ramón De Las Peñas; Amelia Insa; et al; Carlos Camps; Mariano Provencio. (19/23). 2019. Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study) *Lung Cancer*. 135, pp.161-168. ISSN 0169-5002.
- 11 **Scientific paper.** Maria Villalba; Francisco Exposito; Maria Jose Pajares; et al; Carlos Camps; Alfonso Calvo. (10/15). 2019. TMPRSS4: A Novel Tumor Prognostic Indicator for the Stratification of Stage IA Tumors and a Liquid Biopsy Biomarker for NSCLC Patients *Journal Of Clinical Medicine*. 8-12, pp.2134. ISSN 2077-0383.
- 12 **Scientific paper.** J Zugazagoitia; I Ramos; JM Trigo; et al; ;. (7/22). 2018. Clinical utility of plasma-based digital next-generation sequencing in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping. *Annals of Oncology*. ISSN 0923-7534.
- 13 **Scientific paper.** Jesus Garcia Foncillas; Josep Tabernero; Elena Élez; et al; ;. (6/15). 2018. Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer *British Journal of Cancer*. 119, pp.1464-1470. ISSN 0007-0920.

- 14 **Scientific paper.** Ajona, D.; Zanduetta, C.; Corrales, L.; et al; Camps, C.; Lecanda, F.(11/16). 2018. Blockade of the Complement C5a/C5aR1 Axis Impairs Lung Cancer Bone Metastasis by CXCL16-mediated Effects.American journal of respiratory and critical care medicine. 197-9, pp.1164-1176. ISSN 1535-4970.
- 15 **Scientific paper.** Letovanec, I.; Finn, S.; Zygoura, P.; et al; European Thoracic Oncology Platform Lungscape Consortium.2018. Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project.Journal of thoracic oncology.13-3, pp.413-425. ISSN 1556-1380.
- 16 **Scientific paper.** Niki Karachaliou; Jillian Wilhelmina Paulina Bracht; Manuel Fernandez Bruno; et al; Carlos Camps; Rafael Rosell. (12/18). 2018. Association of PALB2 Messenger RNA Expression with platinum-docetaxel efficacy in advanced non-small cell lung cancer.Journal Of Thoracic Oncology. ISSN 1556-0864.
- 17 **Scientific paper.** Herreros-Pomares A; Aguilar-Gallardo C; Calabuig-Fariñas S; Sirera R; Jantus-Lewintre E; Camps C. (AC). (6/6). 2018. EpCAM duality becomes this molecule in a new Dr. Jekyll and Mr. Hyde tale.901796 - Critical Reviews in Oncology Hematology. 126, pp.52-63. ISSN 1040-8428.
- 18 **Scientific paper.** Kerr KM; Dafni U; Schulze K; et al; Camps C; ETOP Lungscape Consortium.(33/42). 2018. Prevalence and clinical association of gene mutations through Multiplex Mutation Testing in patients with NSCLC: Results from the ETOP Lungscape Project.Annals of Oncology. Oxford University Press. 29-1, pp.200-208. ISSN 0923-7534.
- 19 **Scientific paper.** Marta Usó; Eloísa Jantus-Lewintre; Silvia Calabuig; et al; Carlos Camps (AC); Rafael Sirera.(8/9). 2017. Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients.Oncoimmunology. 6-1, pp.e1260214. ISSN 2162-4011.
- 20 **Scientific paper.** Rosell R; Dafni U; Felip E; et al; Thomas M; Stahel RA. (24/35). 2017. Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.Lancet Respiratory Medicine. Elsevier. 5-5, pp.435-444. ISSN 2213-2600.
- 21 **Scientific paper.** Umberto Malapelle; Rafael Sirera; Eloísa Jantus-Lewintre; et al; Carlos Camps (AC). (9/9). 2017. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer Expert Review Of Molecular Diagnostics. 17-3, pp.209-2015. ISSN 1473-7159.
- 22 **Scientific paper.** Usó M; Jantus-Lewintre E; Bremnes RM; et al; Camps C (AC); Sirera R.(13/14). 2016. Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers.Oncotarget. 7-33, pp.52849-52861. ISSN 1949-2553.
- 23 **Scientific paper.** Molina-Pinelo S; Salinas A; Moreno-Mata N; et al; Camps C; Paz-Ares L.(10/12). 2016. Impact of DLK1-DIO3 imprinted cluster hypomethylation in smoker patients with lung cancer.ers.Oncotarget. ISSN 1949-2553.
- 24 **Scientific paper.** Puchades-Carrasco L; Jantus-Lewintre E; Pérez-Rambla C; et al; Camps C; Pineda-Lucena A.(9/10). 2016. Serum metabolomic profiling facilitates the non-invasive identification of metabolic biomarkers associated with the onset and progression of non-small cell lung cancer Oncotarget. 7-11, pp.12904-12916. ISSN 1949-2553.

C.2. Participation in R&D and Innovation projects

- 1 METASTARG: Targeted multifunctional nanoemulsions to interrupt metastasis progression EURONANOMED III ("European Innovative Research & Technological Development Projects in Nanomedicine). Maria De la Fuente. (CIBERONC). 03/06/2019-03/06/2022. 176.550 €. Team member.
- 2 INMUNOGRAMA NO INVASIVO. Aproximación multidimensional para caracterizar y monitorizar el estatus inmune en cáncer de pulmón Eloisa Jantus Lewintre. (CIBER de ONCOLOGÍA (CIBERONC)). 01/01/2019-31/12/2021. 123.420 €. Principal investigator.
- 3 CB16/12/00350, CIBERONc (CIBER Oncología).CB16/12/00350. Instituto de Salud Carlos III. CIBERONC. Carlos Camps Herrero. (Fundación Hospital General Universitario de Valencia). 01/01/2017-31/12/2021. 223.294,78 €. Principal investigator.

- 4 RTC-2017-6597-1, AptaLung. Diagnóstico de cáncer de pulmón utilizando tecnología de aptámeros. Aplicaciones en células tumorales circulantes (CTCs) y en aptahistoquímica. Ministerio de Ciencia e Innovación. María De la Fuente. (Fundación de Investigación Hospital General de Valencia). 01/01/2019-01/06/2021. 467.347,82 €. Team member.
- 5 PI15-00753, Caracterización de la Interacción entre Célula Madre Tumoral y Microambiente Inmune en el Cáncer de Pulmón no Microcítico. Implicaciones Traslacionales. INVESTEN - ISCIII. Carlos Camps Herrero y Eloisa Jantus-Lewintre. (Fundación Hospital General Universitario de Valencia). 01/01/2016-01/12/2019. 50.215 €. Principal investigator.
- 6 RTC-2014-1532-1, Descubrimiento y desarrollo biomarcadores innovadores para medicina personalizada y terapias para el tratamiento eficaz del cáncer de pulmón. Plan Nacional de I+D+I, Ministerio de Economía y Competitividad. Carles Domènech. (Fundación Hospital General Universitario de Valencia). 09/07/2014-09/07/2017. 2.360.639,1 €. Team member.
- 7 RD12/0036/0025, Red Temática de Investigación en Cáncer- Programa de Cáncer de Vías Respiratorias. Spanish Cancer Research Network- Lung and upper respiratory tract cancer program. Red Temática de Investigación Cooperativa en Cáncer- Instituto de Salud Carlos III. Carlos Camps. (Fundación Investigación Hospital General Universitario Valencia). 01/01/2013-31/12/2016. 88.350 €. Principal investigator.
- 8 APM-10-15, Aplicación De La Metabolómica En El Descubrimiento De Nuevos Biomarcadores En Cáncer De Pulmón No Microcítico. Applications of metabolomics for the discovery of new biomarkers in non small cell lung cancer Conselleria de Sanidad de la Comunidad Valenciana. Carlos Camps Herrero. (Fundación Hospital General Universitario de Valencia). 21/05/2015-21/05/2016. 14.216 €. Principal investigator.
- 9 PI12/02838, Identificación de biomarcadores moleculares asociados a células madre tumorales en cáncer de pulmón no microcítico. Implicación en el desarrollo de nuevas estrategias terapéuticas. Identification of cancer stem cell associated molecular biomarkers in non-small cell lung cancer. Implications in the development of new therapeutic strategies. Fondo de Investigación Sanitaria (FIS), Instituto de Salud Carlos III. Carlos Camps. (Fundación Investigación Hospital General Universitario Valencia). 01/01/2013-31/12/2015. 38.115 €.

C.3. Participation in R&D and Innovation contracts

- 1 NGS en Cáncer de Pulmón Lilly España. Carlos Camps Herrero. 01/01/2021-01/01/2022. 540.000 €.
- 2 Biopsia líquida: implementación en la práctica clínica para la búsqueda de biomarcadores en pacientes con cáncer de pulmón no microcítico AstraZeneca Farmacéutica Spain, S.A.. Carlos Camps Herrero. 01/09/2020-01/09/2021. 30.000 €.
- 3 Investigación de la mutación T790M en sangre mediante diferentes metodologías. RING Study Grupo Español de Cáncer de Pulmón. Eloisa Jantus Lewintre. 2018-01/01/2021. 71.677,31 €.
- 4 Estudio Selina: Análisis de mediadores solubles, citoquinas y factores angiogénicos circulantes (FACs), como potenciales factores predictivos/pronósticos en el tratamiento con antiangiogénicos tras un fallo a una primera línea de quimioterapia en el carcinoma de pulmón no escamoso avanzado”. SELINA. Código de protocolo Grupo Español de Cáncer de Pulmón. Javier Puente. (GCEP). 2016-01/01/2019. 151.340 €.
- 5 Estudio de la correspondencia entre el estado mutacional de EGFR en tejido tumoral y células tumorales circulantes (CTCs) en cáncer de pulmón. Validación de la técnica y análisis de su valor pronóstico. Universitat de València; ASTRAZENECA ESPAÑA. Carlos Camps Herrero. (Hospital General Universitario de Valencia). 01/11/2013-02/07/2017. 70.000 €.
- 6 ETOP Lungscape project ETOP. Carlos Camps. (Fundación Investigación Hospital General Universitario Valencia). 09/02/2012-09/02/2021.

C.4. Patents